CoChat
Sign Up
Cited by 36Schizophrenia research and treatmentNeural and Behavioral Psychology StudiesNeurotransmitter Receptor Influence on Behavior

Evaluation of fronto-striatal networks during cognitive control in unmedicated patients with schizophrenia and the effect of antipsychotic medication

Open access
Cadena, Elyse J., White, David M., Kraguljac, Nina V., Reid, Meredith A., Lahti, Adrienne C.·2018·npj Schizophrenia
DOI 10.1038/s41537-018-0051-yPMC PMC5938238
Open this paper in CoChat — free accountOpen PDF

Abstract

To understand the mechanism of cognitive control dysfunction in schizophrenia, it is critical to characterize brain function without the confounding effect of medication. It is also important to establish the extent to which antipsychotic medication restores brain function and whether those changes are related to psychosis improvement. Twenty-two patients with schizophrenia, initially unmedicated and after a 6-week course of risperidone, and 20 healthy controls (HC) studied twice, 6 weeks apart, performed an fMRI task. We examined group and longitudinal differences in anterior cingulate cortex (ACC), striatum, and midbrain functional activity during performance of a Stroop color task as well as activity patterns associated with improvement in psychosis symptoms. Unmedicated patients showed reduced functional activity in the ACC, striatum, and midbrain compared to HC. Post hoc contrasts from significant group-by-time interactions indicated that, in patients, drug administration was associated with both activity increases and decreases. In unmedicated patients, greater baseline functional activity in the striatum and midbrain predicted subsequent better treatment response. Greater changes in functional activity in ACC and ventral putamen over the course of 6 weeks positively correlated with better treatment response. Unmedicated patients show reduced activity in brain networks pivotal for cognitive control and medication is associated with functional changes in these regions. These results suggest a mechanism by which antipsychotic medication has a beneficial effect on cognition. Our results also support the notion that treatment response is determined by a combination of the baseline pattern of brain function and by the pharmacological modulation of these regions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41537-018-0051-y

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. [1]Ongur D Default mode network abnormalities in bipolar disorder and schizophrenia Psychiatry Res 2010 183 59 68 10.1016/j.pscychresns.2010.04.008 20553873 PMC2902695 · DOI
  2. [2]Quide Y Morris RW Shepherd AM Rowland JE Green MJ Task-related fronto-striatal functional connectivity during working memory performance in schizophrenia Schizophr. Res. 2013 150 468 475 10.1016/j.schres.2013.08.009 24016726 · DOI · Paper page
  3. [3]Sarpal DK Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia JAMA Psychiatry 2015 72 5 13 10.1001/jamapsychiatry.2014.1734 25372846 PMC4286512 · DOI
  4. [4]Segarra N Abnormal frontostriatal activity during unexpected reward receipt in depression and schizophrenia: relationship to anhedonia Neuropsychopharmacology 2016 41 2001 2010 10.1038/npp.2015.370 26708106 PMC4820052 · DOI
  5. [5]Zandbelt BB van Buuren M Kahn RS Vink M Reduced proactive inhibition in schizophrenia is related to corticostriatal dysfunction and poor working memory Biol. Psychiatry 2011 70 1151 1158 10.1016/j.biopsych.2011.07.028 21903198 · DOI
  6. [6]Laruelle M SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: an experimental validation of the dopamine hypothesis of schizophrenia Schizophr. Res. 1996 18 198 199 10.1016/0920-9964(96)85619-2 · DOI
  7. [7]Cole DM Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability Cereb. Cortex 2012 22 2784 2793 10.1093/cercor/bhr354 22186675 · DOI
  8. [8]Nagano-Saito A Dopamine depletion impairs frontostriatal functional connectivity during a set-shifting task J. Neurosci. 2008 28 3697 3706 10.1523/JNEUROSCI.3921-07.2008 18385328 PMC6671089 · DOI · Paper page
  9. [9]Lahti AC Holcomb HH Weiler MA Medoff DR Tamminga CA Functional effects of antipsychotic drugs: comparing clozapine with haloperidol Biol. Psychiatry 2003 53 601 608 10.1016/S0006-3223(02)01602-5 12679238 · DOI
  10. [10]Lahti AC Weiler MA Medoff DR Tamminga CA Holcomb HH Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia Psychiatry Res. 2005 139 19 30 10.1016/j.pscychresns.2005.02.006 15950442 · DOI
  11. [11]Lahti AC Weiler MA Holcomb HH Tamminga CA Cropsey KL Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia Neuropsychopharmacology 2009 34 2675 2690 10.1038/npp.2009.94 19675535 PMC2784027 · DOI
  12. [12]Svensson TH Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs Brain Res. Brain Res. Rev. 2000 31 320 329 10.1016/S0165-0173(99)00048-X 10719159 · DOI
  13. [13]Bari A Robbins TW Inhibition and impulsivity: behavioral and neural basis of response control Prog. Neurobiol. 2013 108 44 79 10.1016/j.pneurobio.2013.06.005 23856628 · DOI · Paper page
  14. [14]Vernaleken I ‘Prefrontal’ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation Hum. Brain Mapp. 2007 28 931 939 10.1002/hbm.20325 17133402 PMC6871482 · DOI
  15. [15]Ghahremani DG Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans J. Neurosci. 2012 32 7316 7324 10.1523/JNEUROSCI.4284-11.2012 22623677 PMC3517177 · DOI · Paper page
  16. [16]Kudlicka A Clare L Hindle JV Executive functions in Parkinson’s disease: systematic review and meta-analysis Mov. Disord. 2011 26 2305 2315 10.1002/mds.23868 21971697 · DOI
  17. [17]Hadley JA Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia Neuropsychopharmacology 2014 39 1020 1030 10.1038/npp.2013.305 24165885 PMC3924537 · DOI
  18. [18]Kraguljac NV Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone Neuroimage Clin. 2016 10 146 158 10.1016/j.nicl.2015.11.015 26793436 PMC4683457 · DOI
  19. [19]Lesh TA A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia JAMA Psychiatry 2015 72 226 234 10.1001/jamapsychiatry.2014.2178 25588194 PMC4794273 · DOI
  20. [20]Lahti AC Clozapine but not haloperidol re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex Neuropsychopharmacology 2004 29 171 178 10.1038/sj.npp.1300312 14520337 · DOI
  21. [21]Arvanitis LA Miller BG Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group Biol. Psychiatry 1997 42 233 246 10.1016/S0006-3223(97)00190-X 9270900 · DOI
  22. [22]Small JG Hirsch SR Arvanitis LA Miller BG Link CG Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group Arch. Gen. Psychiatry 1997 54 549 557 10.1001/archpsyc.1997.01830180067009 9193196 · DOI
  23. [23]Kumra S Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison Biol. Psychiatry 2008 63 524 529 10.1016/j.biopsych.2007.04.043 17651705 · DOI
  24. [24]Ferenczi EA Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior Science 2016 351 aac9698 10.1126/science.aac9698 26722001 PMC4772156 · DOI · Paper page
  25. [25]Lohani, S., Poplawsky, A. J., Kim, S. G. & Moghaddam, B. Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI. Mol. Psychiatry10.1038/mp.2016.102 (2016). PMC5269559 27457809
  26. [26]Grace AA Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression Nat. Rev. Neurosci. 2016 17 524 532 10.1038/nrn.2016.57 27256556 PMC5166560 · DOI · Paper page
  27. [28]Yoon JH Minzenberg MJ Raouf S D’Esposito M Carter CS Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia Biol. Psychiatry 2013 74 122 129 10.1016/j.biopsych.2012.11.018 23290498 PMC3620727 · DOI
  28. [29]Yoon JH Task-evoked substantia nigra hyperactivity associated with prefrontal hypofunction, prefrontonigral disconnectivity and nigrostriatal connectivity predicting psychosis severity in medication naive first episode schizophrenia Schizophr. Res. 2014 159 521 526 10.1016/j.schres.2014.09.022 25266549 PMC6921934 · DOI
  29. [30]Keefe RS Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch. Gen. Psychiatry 2007 64 633 647 10.1001/archpsyc.64.6.633 17548746 · DOI
  30. [31]MacDonald AW 3rd Cohen JD Stenger VA Carter CS Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control Science 2000 288 1835 1838 10.1126/science.288.5472.1835 10846167 · DOI · Paper page
  31. [32]Yucel M Anterior cingulate dysfunction: implications for psychiatric disorders? J. Psychiatry Neurosci. 2003 28 350 354 14517578 PMC193981
  32. [33]Margulies DS Mapping the functional connectivity of anterior cingulate cortex Neuroimage 2007 37 579 588 10.1016/j.neuroimage.2007.05.019 17604651 · DOI
  33. [34]Snitz BE Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment Am. J. Psychiatry 2005 162 2322 2329 10.1176/appi.ajp.162.12.2322 16330597 · DOI
  34. [35]Dazzan P Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research Schizophr. Bull. 2015 41 574 583 10.1093/schbul/sbv024 25800248 PMC4393706 · DOI
  35. [36]Kraguljac NV Aberrant hippocampal connectivity in unmedicated patients with schizophrenia and effects of antipsychotic medication: a longitudinal resting state functional MRI study Schizophr. Bull. 2016 42 1046 1055 10.1093/schbul/sbv228 26873890 PMC4903060 · DOI
  36. [37]Ngan ET Lane CJ Ruth TJ Liddle PF Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change J. Neurol. Neurosurg. Psychiatry 2002 72 106 110 10.1136/jnnp.72.1.106 11784835 PMC1737716 · DOI
  37. [38]Holcomb HH Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol Am. J. Psychiatry 1996 153 41 49 10.1176/ajp.153.1.41 8540590 · DOI
  38. [39]Miller DD Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography Neuropsychopharmacology 1997 17 230 240 10.1016/S0893-133X(97)00042-0 9326747 · DOI
  39. [40]Wang J Cognitive effects of atypical antipsychotic drugs in first-episode drug-naive schizophrenic patients Neural Regen. Res. 2013 8 277 286 25206599 PMC4107525
  40. [41]Goldberg TE Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry 2007 64 1115 1122 10.1001/archpsyc.64.10.1115 17909123 · DOI
  41. [42]Murty VP Resting state networks distinguish human ventral tegmental area from substantia nigra Neuroimage 2014 100 580 589 10.1016/j.neuroimage.2014.06.047 24979343 PMC4370842 · DOI
  42. [43]Carpenter WT Jr. Decisional capacity for informed consent in schizophrenia research Arch. Gen. Psychiatry 2000 57 533 538 10.1001/archpsyc.57.6.533 10839330 · DOI
  43. [44]Nurnberger JI Diagnostic Interview for Genetic-Studies - rationale, unique features, and training Arch. Gen. Psychiatry 1994 51 849 859 10.1001/archpsyc.1994.03950110009002 7944874 · DOI
  44. [45]Randolph C Tierney MC Mohr E Chase TN The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity J. Clin. Exp. Neuropsychol. 1998 20 310 319 10.1076/jcen.20.3.310.823 9845158 · DOI · Paper page
  45. [46]Overall JE Gorham DE The Brief Psychiatric Rating Scale Psychol. Rep. 1962 10 799 812 10.2466/pr0.1962.10.3.799 · DOI · Paper page
  46. [47]Becker TM Kerns JG MacDonald AW Carter CS Prefrontal dysfunction in first-degree relatives of schizophrenia patients during a Stroop task Neuropsychopharmacology 2008 33 2619 2625 10.1038/sj.npp.1301673 18216774 · DOI
  47. [48]Mazaika PK Hoeft F Glover GH Reiss AL Methods and software for fMRI analysis of clinical subjects Neuroimage 2009 47 S58 10.1016/S1053-8119(09)70238-1 · DOI
  48. [49]Reid MA Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia Biol. Psychiatry 2010 68 625 633 10.1016/j.biopsych.2010.04.013 20570244 PMC2953853 · DOI
  49. [50]Maldjian JA Laurienti PJ Kraft RA Burdette JH An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets Neuroimage 2003 19 1233 1239 10.1016/S1053-8119(03)00169-1 12880848 · DOI

Cited by

Sorted by citations

Authors
Cadena, E. J., White, D. M., Kraguljac, N. V., Reid, M. A., & Lahti, A. C.
Affiliations
  • University of Alabama at Birmingham (US)
  • Auburn University (US)
Corresponding author
Lahti, Adrienne C.
ORCID
Venue
npj Schizophrenia
Publisher
Springer Science and Business Media LLC
Published
2018-05-07
Volume
4
Issue
1
Pages
8-8
ISSN
2334-265X (ISSN-L)
DOI
10.1038/s41537-018-0051-y
PMC
PMC5938238
OpenAlex
W2801311661
Cited by
36
References
1
Citations by year
2025: 4 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2
FWCI
2.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Schizophrenia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (R01MH102951)
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
cognitive control, fronto-striatal network, antipsychotic drugs, risperidone, unmedicated patients, anterior cingulate cortex, striatum, midbrain, ventral putamen, Stroop task, treatment response, psychotic symptoms, pharmacological modulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review